Cognitive impairment and chemotherapy: a brief overview

Milena Vitali, Carla Ida Ripamonti, Fausto Roila, Claudia Proto, Diego Signorelli, Martina Imbimbo, Giulia Corrao, Angela Brissa, Gallucci Rosaria, Filippo de Braud, Marina Chiara Garassino, Giuseppe Lo Russo

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Patients with cancer are experiencing long-term survival following chemotherapy, but the treatment may also be associated with short and long-term toxicity, including the possibility of cognitive dysfunction. A literature overview indicated a significant association between chemotherapy and cognitive impairment but prospective longitudinal research is warranted to examine the degree and persisting nature of this decline. Although chemotherapeutic agents are unlikely to cross the blood-brain barrier, it has been alleged that the occurrence of neurotoxicity is linked to the pro-inflammatory cytokine pathways. Moreover in most cases many other factors could play an ancillary and concomitant role. The contribution of hormone therapy as well as emotional, social, behavioural and genetic factors should always be considered. Especially physical activity and cognitive training appear promising in the management of cognitive impairment but additional studies are required to establish their efficacy.

Original languageEnglish
Pages (from-to)7-14
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume118
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Drug Therapy
Behavioral Genetics
Blood-Brain Barrier
Hormones
Exercise
Cytokines
Survival
Therapeutics
Research
Cognitive Dysfunction
Neoplasms

Keywords

  • Cancer
  • Chemotherapy-related toxicity
  • Cognitive impairment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

Cognitive impairment and chemotherapy : a brief overview. / Vitali, Milena; Ripamonti, Carla Ida; Roila, Fausto; Proto, Claudia; Signorelli, Diego; Imbimbo, Martina; Corrao, Giulia; Brissa, Angela; Rosaria, Gallucci; de Braud, Filippo; Garassino, Marina Chiara; Lo Russo, Giuseppe.

In: Critical Reviews in Oncology/Hematology, Vol. 118, 01.10.2017, p. 7-14.

Research output: Contribution to journalReview article

Vitali, Milena ; Ripamonti, Carla Ida ; Roila, Fausto ; Proto, Claudia ; Signorelli, Diego ; Imbimbo, Martina ; Corrao, Giulia ; Brissa, Angela ; Rosaria, Gallucci ; de Braud, Filippo ; Garassino, Marina Chiara ; Lo Russo, Giuseppe. / Cognitive impairment and chemotherapy : a brief overview. In: Critical Reviews in Oncology/Hematology. 2017 ; Vol. 118. pp. 7-14.
@article{fa8b3150a93b4f32a9f43320442e944f,
title = "Cognitive impairment and chemotherapy: a brief overview",
abstract = "Patients with cancer are experiencing long-term survival following chemotherapy, but the treatment may also be associated with short and long-term toxicity, including the possibility of cognitive dysfunction. A literature overview indicated a significant association between chemotherapy and cognitive impairment but prospective longitudinal research is warranted to examine the degree and persisting nature of this decline. Although chemotherapeutic agents are unlikely to cross the blood-brain barrier, it has been alleged that the occurrence of neurotoxicity is linked to the pro-inflammatory cytokine pathways. Moreover in most cases many other factors could play an ancillary and concomitant role. The contribution of hormone therapy as well as emotional, social, behavioural and genetic factors should always be considered. Especially physical activity and cognitive training appear promising in the management of cognitive impairment but additional studies are required to establish their efficacy.",
keywords = "Cancer, Chemotherapy-related toxicity, Cognitive impairment",
author = "Milena Vitali and Ripamonti, {Carla Ida} and Fausto Roila and Claudia Proto and Diego Signorelli and Martina Imbimbo and Giulia Corrao and Angela Brissa and Gallucci Rosaria and {de Braud}, Filippo and Garassino, {Marina Chiara} and {Lo Russo}, Giuseppe",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.critrevonc.2017.08.001",
language = "English",
volume = "118",
pages = "7--14",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Cognitive impairment and chemotherapy

T2 - a brief overview

AU - Vitali, Milena

AU - Ripamonti, Carla Ida

AU - Roila, Fausto

AU - Proto, Claudia

AU - Signorelli, Diego

AU - Imbimbo, Martina

AU - Corrao, Giulia

AU - Brissa, Angela

AU - Rosaria, Gallucci

AU - de Braud, Filippo

AU - Garassino, Marina Chiara

AU - Lo Russo, Giuseppe

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Patients with cancer are experiencing long-term survival following chemotherapy, but the treatment may also be associated with short and long-term toxicity, including the possibility of cognitive dysfunction. A literature overview indicated a significant association between chemotherapy and cognitive impairment but prospective longitudinal research is warranted to examine the degree and persisting nature of this decline. Although chemotherapeutic agents are unlikely to cross the blood-brain barrier, it has been alleged that the occurrence of neurotoxicity is linked to the pro-inflammatory cytokine pathways. Moreover in most cases many other factors could play an ancillary and concomitant role. The contribution of hormone therapy as well as emotional, social, behavioural and genetic factors should always be considered. Especially physical activity and cognitive training appear promising in the management of cognitive impairment but additional studies are required to establish their efficacy.

AB - Patients with cancer are experiencing long-term survival following chemotherapy, but the treatment may also be associated with short and long-term toxicity, including the possibility of cognitive dysfunction. A literature overview indicated a significant association between chemotherapy and cognitive impairment but prospective longitudinal research is warranted to examine the degree and persisting nature of this decline. Although chemotherapeutic agents are unlikely to cross the blood-brain barrier, it has been alleged that the occurrence of neurotoxicity is linked to the pro-inflammatory cytokine pathways. Moreover in most cases many other factors could play an ancillary and concomitant role. The contribution of hormone therapy as well as emotional, social, behavioural and genetic factors should always be considered. Especially physical activity and cognitive training appear promising in the management of cognitive impairment but additional studies are required to establish their efficacy.

KW - Cancer

KW - Chemotherapy-related toxicity

KW - Cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=85030623070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030623070&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2017.08.001

DO - 10.1016/j.critrevonc.2017.08.001

M3 - Review article

C2 - 28917271

AN - SCOPUS:85030623070

VL - 118

SP - 7

EP - 14

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -